Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Clinical Trial of GenSci136 in Patients With Myasthenia Gravis

2026. november 11. frissítette: Changchun GeneScience Pharmaceutical Co., Ltd.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Trial (Including an Open-Label Extension Phase) to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of GenSci136 for Injection in Patients With Myasthenia Gravis

Phase Ib/II Clinical Trial of GenSci136 in Patients with Myasthenia Gravis

A tanulmány áttekintése

Állapot

Még nincs toborzás

Körülmények

Beavatkozás / kezelés

Részletes leírás

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Trial (Including an Open-Label Extension Phase) to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of GenSci136 for Injection in Patients with Myasthenia Gravis

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

72

Fázis

  • 2. fázis
  • 1. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányi helyek

  • Kína
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kína, 200032
        • Huashan Hospital ,Fudan University

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  1. Male or female, aged 18 to 70 years (both inclusive).
  2. standard-of-care (SoC) treatment for MG before screening.
  3. Men of reproductive age and women of childbearing potential must agree to take highly effective contraceptive methods from screening to 5 months after the last dose4. Participants who can understand the trial procedures, voluntarily participate in the trial (themselves or through their legally acceptable representative), For participants with gMG: 1. Participants diagnosed with gMG with generalized muscle weakness, corresponding to Myasthenia Gravis Foundation of America (MGFA) clinical classification Class II-IV

2. Positive for anti-AChR antibodies or anti-MuSK antibodies. 3. MG-ADL score must be ≥ 6, and the ocular score must account for < 50% of the total score. 4. QMG score must be ≥ 8, with at least 4 individual items scored ≥ 2. For participants with oMG: 1. Participants with a diagnosis of MG supported by the following medical documentation: a. Positive anti-AChR or anti-MuSK autoantibodies; or b. Abnormal neuromuscular transmission confirmed by single-fiber electromyography (SFEMG)/repetitive nerve stimulation (RNS), together with at least one of the following pharmacological/clinical confirmations: 1) documented positive ice pack test (resolution of ptosis after application of an ice pack to the eyelid for 2 minutes, with an improvement of > 2 mm); 2) documented positive edrophonium chloride (Tensilon) test, or a positive test with another cholinesterase inhibitor currently used in clinical practice to confirm oMG, such as the neostigmine test; or 3) documented improvement in MG signs following treatment with oral AChE inhibitors, plasma exchange, IVIg, glucocorticoids, or other relevant therapies. 2. Participants diagnosed with oMG, corresponding to MGFA clinical classification Class I. 3. the MGII (PRO) ocular score must be ≥ 6, and at least 2 ocular items must have a score of ≥ 2. 4. No pupillary abnormalities, except those caused by previous localized disease or surgery.

Exclusion Criteria:

  1. Known hypersensitivity to GenSci136 or any of the excipients contained in the GenSci136 formulation, or history of serious hypersensitivity reactions to any drug
  2. Participants with diseases or dysfunctions (excluding MG) known to interfere with the clinical trial,
  3. Participants with a known history of malignant tumors (including but not limited to lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, prostate cancer, thyroid cancer, bladder cancer, pancreatic cancer, kidney cancer, breast cancer, cervical cancer, corpus uteri cancer, ovarian cancer and malignant melanoma) are excluded unless they have been free of recurrence for ≥ 3 years; basal cell carcinoma, non-metastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, breast carcinoma in situ, and incidental prostate cancer T1a/T1b are not excluded under this criterion (for thymoma-related requirements, see Exclusion Criterion 8).
  4. Presence of acute or chronic infections requiring treatment at screening.
  5. History of MG crisis within 1 month before screening.
  6. Diagnosis of any other autoimmune disease at screening other than MG, e.g., rheumatoid arthritis, Sjögren's syndrome (patients with abnormal thyroid function at screening will be excluded; those with autoimmune thyroiditis under stable control for ≥ 6 months and with normal thyroid function at screening may be exempted). 7. Participants who have attempted suicide within the past year or are currently at risk of impulsive behavior or suicide. 8. Participants with current or prior thymoma or thymectomy (except those meeting the criteria specified below), or planned thymectomy during the trial period. 9. Receipt of any live or live attenuated vaccine within 1 month before screening, or planned receipt of any live or live attenuated vaccine (except inactivated vaccine) during the trial period. 10. Receipt of intravenous, subcutaneous, or intramuscular immunoglobulin or plasma exchange within 1 month before screening. 11. Treatment with any form of CAR-T cell therapy, T-cell engager (TCE) therapy, or biologics targeting CD19/CD20 within 1 year before screening. 12. Positive hepatitis B virus at screening [hepatitis B surface antigen (HBsAg) positive; or HBsAg negative with hepatitis B core antibody (HBcAb) positive and hepatitis B virus deoxyribonucleic acid (HBV-DNA) positive or > upper limit of normal (ULN)], positive hepatitis C virus antibody (HCV-Ab), positive human immunodeficiency virus antibody (HIV-Ab), or positive syphilis serology test. 13. 12-lead ECG abnormalities during the screening period or at baseline, e.g., heart rate-corrected QT interval QTcF absolute value > 470 ms (Fridericia's formula: QTcF = QT/RR0.33) that, upon assessment by the investigator, may interfere with this clinical trial. 14. During the screening or baseline period, participants with any of the following abnormal laboratory test results: a) Absolute neutrophil count (ANC) < 1.2 × 10³/μL ; b) Platelet count < 75,000/μL (i.e., < 75 × 10⁹/L); c) Hemoglobin < 8.0 g/dL; d) IgG < 600 mg/dL; e) Creatinine > 1.5 × ULN or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2; f) Glycated hemoglobin (HbA1c) > 8.0%, except for participants whose blood glucose control is considered adequate by the investigator; g) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN), or total bilirubin (TBIL) > 1.5 × ULN; h) Other abnormal laboratory test results deemed by the investigator to make the participant unsuitable for participation in the study. 15. Participants judged by the investigator to be ineligible for other reasons.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Kettős

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: GenSci136 for injection
Drog: GenSci136 for injection

GenSci136 for injection, administered the medication according to the requirements of the protocal
Placebo Comparator: GenSci136 blank excipient(placebo) for injection
Drog: GenSci136 for injection

GenSci136 for injection, administered the medication according to the requirements of the protocal

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Időkeret
Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).
Időkeret: From time of informed consent to 10 weeks after the first dose of GenSci136
From time of informed consent to 10 weeks after the first dose of GenSci136
Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).
Időkeret: Approximately 26 weeks
Approximately 26 weeks

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
area under the concentration-time curve from time 0 to time t of the last quantifiable concentration (AUC0-t)
Időkeret: Approximately 10 weeks.
Approximately 10 weeks.
area under the concentration-time curve from time 0 to infinity (AUC0-∞)
Időkeret: Approximately 10 weeks
Approximately 10 weeks
area under the concentration-time curve from time 0 to time τ (AUC0-τ)
Időkeret: Approximately 10 weeks
Approximately 10 weeks
maximum concentration (Cmax)
Időkeret: Approximately 10 weeks
Approximately 10 weeks
time to maximum concentration (Tmax)
Időkeret: Approximately 10 weeks
Approximately 10 weeks
apparent clearance (CL/F)
Időkeret: Approximately 10 weeks
Approximately 10 weeks
apparent volume of distribution (Vd/F)
Időkeret: Approximately 10 weeks
Approximately 10 weeks
Changes from baseline in free and total A proliferation-inducing ligand (APRIL) levels
Időkeret: Approximately 10 weeks
Approximately 10 weeks
Changes from baseline in free and total B-cell activating factor (BAFF) levels
Időkeret: Approximately 10 weeks
Approximately 10 weeks
Change from baseline in MG-ADL score at Week 48
Időkeret: Approximately 48 Weeks

The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24. Higher scores indicate greater disease severity and worse functional status.
Approximately 48 Weeks
Proportion of participants with a ≥ 2-point reduction from baseline in MG-ADL score at Week 26 and Week 48
Időkeret: Approximately 48 Weeks

The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24. Higher scores indicate greater disease severity and worse functional status.
Approximately 48 Weeks
Proportion of participants with a ≥ 3-point reduction from baseline in QMG score at Week 26 and Week 48
Időkeret: Approximately 48 Weeks

The Quantitative Myasthenia Gravis (QMG) score is a 13-item clinician-administered measure used to assess muscle weakness and disease severity in patients with myasthenia gravis. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 39. Higher scores indicate greater disease severity and worse clinical outcomes.
Approximately 48 Weeks
Proportion of participants with minimal symptom expression (MSE, MG-ADL score of 0 or 1) at Week 26 and Week 48
Időkeret: Approximately 48 Weeks

Minimal symptom expression (MSE) is defined as a Myasthenia Gravis Activities of Daily Living (MG-ADL) total score of 0 or 1. The MG-ADL is an 8-item scale used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24, with higher scores indicating greater disease severity and worse functional status.
Approximately 48 Weeks
Change from baseline in total Myasthenia Gravis Composite (MGC) score at Week 26 and Week 4
Időkeret: Approximately 26 Weeks

The Myasthenia Gravis Composite (MGC) is a validated 10-item assessment tool used to evaluate the clinical severity of myasthenia gravis, incorporating both physician-assessed and patient-reported measures. The total score ranges from 0 to 50, with higher scores indicating greater disease severity and worse clinical outcomes
Approximately 26 Weeks
Change from baseline in Revised Myasthenia Gravis Quality of Life-15 (MG-QoL15r) score at Week 26 and Week 48
Időkeret: Approximately 48 Weeks

The Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) is a patient-reported questionnaire used to assess the impact of myasthenia gravis on health-related quality of life. It consists of 15 items, each scored from 0 to 2, resulting in a total score ranging from 0 to 30. Higher scores indicate greater impairment in quality of life and worse clinical outcomes.
Approximately 48 Weeks
Change from baseline in EuroQol Five-Dimension Five-Level (EQ-5D-5L) score at Week 26 and Week 48
Időkeret: Approximately 48 Weeks

The EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire is a standardized measure of health-related quality of life comprising five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels, ranging from 1 (no problems) to 5 (extreme problems). Responses are converted into a health utility index. The EQ Visual Analogue Scale (EQ-VAS) assesses participants' self-rated overall health status on a scale from 0 (worst imaginable health) to 100 (best imaginable health). Higher Index and EQ-VAS scores indicate better health status.
Approximately 48 Weeks
Change from baseline in MG-ADL score over time
Időkeret: Approximately 48 Weeks

The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24. Higher scores indicate greater disease severity and worse functional status.
Approximately 48 Weeks
Change from baseline in QMG score over time
Időkeret: Approximately 48 Weeks

The Quantitative Myasthenia Gravis (QMG) score is a 13-item clinician-administered measure used to assess muscle weakness and disease severity in patients with myasthenia gravis. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 39. Higher scores indicate greater disease severity and worse clinical outcomes.
Approximately 48 Weeks
Change from baseline in MGC score over time
Időkeret: Approximately 48 Weeks

The Myasthenia Gravis Composite (MGC) is a validated 10-item assessment tool used to evaluate the clinical severity of myasthenia gravis, incorporating both physician-assessed and patient-reported measures. The total score ranges from 0 to 50, with higher scores indicating greater disease severity and worse clinical outcomes.
Approximately 48 Weeks
Change from baseline in MG-QoL15r score over time
Időkeret: Approximately 48 Weeks

The Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) is a patient-reported questionnaire used to assess the impact of myasthenia gravis on health-related quality of life. It consists of 15 items, each scored from 0 to 2, resulting in a total score ranging from 0 to 30. Higher scores indicate greater impairment in quality of life and worse clinical outcomes.
Approximately 48 Weeks
Change from baseline in EQ-5D-5L score over time
Időkeret: Approximately 48 Weeks

The EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire is a standardized measure of health-related quality of life comprising five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels, ranging from 1 (no problems) to 5 (extreme problems). Responses are converted into a health utility index. The EQ Visual Analogue Scale (EQ-VAS) assesses participants' self-rated overall health status on a scale from 0 (worst imaginable health) to 100 (best imaginable health). Higher Index and EQ-VAS scores indicate better health status.
Approximately 48 Weeks
Change from baseline in ocular score of the Myasthenia Gravis Impairment Index (participant-reported outcomes) [MGII (PRO)] at Week 26 and Week 48
Időkeret: Approximately 48 weeks

The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising 22 patient-reported outcome (PRO) items and 6 physical examination (PE) items. The MGII ocular PRO score consists of 6 patient-reported items assessing the frequency, severity, and impact of diplopia and ptosis. Each item is scored from 0 to 3, yielding a total ocular PRO score ranging from 0 to 18. Higher scores indicate more severe ocular symptoms.
Approximately 48 weeks
Change from baseline in ocular score of the Myasthenia Gravis Impairment Index (Participant-reported Outcome and Physical Examination) (MGII [PRO+PE]) at Week 26 and Week 48
Időkeret: Approximately 48 weeks

The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising 22 patient-reported outcome (PRO) items and 6 physical examination (PE) items. The MGII ocular PRO+PE score combines 6 patient-reported items and 2 clinician-assessed physical examination items evaluating diplopia and ptosis. The score is calculated as the sum of these 8 items, ranging from 0 to 23. Higher scores indicate more severe ocular impairment
Approximately 48 weeks
Change from baseline in ocular score of the MGII (PE) at Week 26 and Week 48
Időkeret: Approximately 48 weeks

The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising patient-reported and physical examination components. The MGII ocular physical examination (PE) score consists of 2 clinician-assessed items evaluating diplopia (scored from 0 to 3) and ptosis (scored from 0 to 2). The total ocular PE score ranges from 0 to 5, with higher scores indicating more severe ocular impairment.
Approximately 48 weeks
Changes from baseline in total MGII score at Week 26 and Week 48
Időkeret: Approximately 48 weeks
Approximately 48 weeks
Changes from baseline in the incidence and severity of TEAEs
Időkeret: Approximately 64 weeks

The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising 28 items, including 22 patient-reported outcome (PRO) items and 6 physical examination (PE) items. The MGII evaluates ocular and generalized impairments, including symptoms affecting ocular, bulbar, respiratory, and limb muscle function. The total score is calculated as the sum of all 28 items and ranges from 0 to 84. Higher scores indicate greater disease severity and impairment.
Approximately 64 weeks
Changes from baseline in the incidence and severity of SAEs
Időkeret: Approximately 64 weeks
Approximately 64 weeks
steady-state maximum concentration (Cmax, ss)
Időkeret: Approximately 64 weeks
Approximately 64 weeks
steady-state trough concentration (Cmin, ss)
Időkeret: Approximately 64 weeks
Approximately 64 weeks
time to steady-state maximum concentration (Tmax, ss)
Időkeret: Approximately 64 weeks
Approximately 64 weeks
mean concentration at steady state (Cav, ss)
Időkeret: Approximately 64 weeks
Approximately 64 weeks
area under the concentration-time curve over the dosing interval at steady state (AUC0-τ, ss)
Időkeret: Approximately 64 weeks
Approximately 64 weeks
Changes from baseline in free and total APRIL levels
Időkeret: Approximately 64 weeks
Approximately 64 weeks
Changes from baseline in free and total BAFF levels
Időkeret: Approximately 64 weeks
Approximately 64 weeks

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Changchun GeneScience Pharmaceutical Co., Ltd.

Nyomozók

  • Kutatásvezető: Sushan Luo, Huashan Hospital
  • Kutatásvezető: Bitao Bu, Tongji Hospital

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. december 1.

Elsődleges befejezés (Becsült)

2028. december 1.

A tanulmány befejezése (Becsült)

2029. június 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. október 27.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 11.

Első közzététel (Tényleges)

2026. november 13.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 13.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 11.

Utolsó ellenőrzés

2026. október 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

További vonatkozó MeSH feltételek

Egyéb vizsgálati azonosító számok

  • GenSci136-201

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel